Meeting
2016 ASCO Annual Meeting
Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma.
Authors
Khe Hoang-Xuan
AP-HP, Hôpital La Pitié Salpêtrière, IGCNO, Paris, France
Khe Hoang-Xuan , Andreas Hottinger , Louis Royer-Perron , Agusti Alentorn , Julien Savatovsky , Rita De Micheli , Krisztian Homicsko , Sebastien Banquet , Jeanne Pauly , Isabelle Sudey , Roger Tell , Patrick Therasse , Maryline Barrie , Chantal Campello , Olivier L. Chinot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
2013-003079-37
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2033)
DOI
10.1200/JCO.2016.34.15_suppl.2033
Abstract #
2033
Poster Bd #
222
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
![EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.](https://d201v5jt9ylckg.cloudfront.net/316/15821/233888/233888_A322_poster_pv.jpg)
EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.
First Author: Thomas Lillie
Poster
2018 ASCO Annual Meeting
A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma.
First Author: John Frederick De Groot
Poster
2018 ASCO Annual Meeting
Hypofractionnated stereotactic radiotherapy and anti-PDL1 durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial.
First Author: Damien Pouessel
Poster
2015 ASCO Annual Meeting
Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.
First Author: Annick Desjardins